Welcome to our dedicated page for Cuprina Holdings (Cayman) news (Ticker: CUPR), a resource for investors and traders seeking the latest updates and insights on Cuprina Holdings (Cayman) stock.
Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) is a Singapore-based biomedical and biotechnology company active in chronic wound management, infertility, medical waste recycling and cosmeceuticals. The news flow around Cuprina reflects its efforts to develop and commercialize products across these areas, as well as its regulatory and capital markets developments.
News articles on this page cover Cuprina’s updates on MEDIFLY maggot debridement therapy for chronic wounds, including expansion plans through its associate Cuprina MENA Co. Ltd in Saudi Arabia to supply MEDIFLY products across the Middle East and North Africa region. Coverage also includes the company’s agreement to license an FDA-cleared medical maggot product for use in the United States and its exclusive rights to sell medicinal leeches in Gulf Cooperation Council countries.
Investors will find announcements about Cuprina’s diversification into infertility-related IVF media production in Singapore, its joint venture with Aiodine Laboratory to develop and market an iodine-based disinfectant solution for chronic and acute wounds and antiseptic uses, and its research collaborations on bullfrog-derived collagen peptides for wound care and cosmeceutical applications. News items also track the company’s licensing of a UNIDO/GEF-demonstrated medical waste recycling technology and its Memorandum of Understanding with Singapore Biowaste Solutions to explore integrating this process into existing waste management facilities.
Regulatory and market updates, such as the Nasdaq minimum bid price notification letter and participation in investor-focused events, are also part of Cuprina’s news record. Readers can use this page to follow company press releases, research updates, strategic agreements and other disclosures related to CUPR.
Cuprina Holdings (NASDAQ: CUPR) announced the successful closing of its underwriter's over-allotment option following its IPO, selling an additional 450,000 Class A ordinary shares at $4.00 per share. Combined with the previously announced IPO proceeds of $12 million, the company has raised total gross proceeds of $13.8 million. R. F. Lafferty & Co. served as the sole book-running manager for the offering.
Cuprina, a biomedical and biotechnology company, focuses on developing products for chronic wound management, infertility treatments, and cosmeceuticals for the health and beauty sector. The offering was conducted under the company's Form F-1 registration statement, which became effective on March 31, 2025.
Cuprina Holdings (Nasdaq: CUPR) has successfully completed its Initial Public Offering (IPO), raising $12.0 million in gross proceeds through the sale of 3,000,000 Class A Ordinary Shares at $4.00 per share. Trading began on NASDAQ on April 10, 2025, under the symbol 'CUPR'.
The company, focused on chronic wound management and cosmeceuticals, plans to utilize the net proceeds for:
- Market expansion
- R&D activities and product portfolio expansion
- Brand awareness building
- Equipment and infrastructure investment
- Working capital and general corporate purposes
R. F. Lafferty & Co. served as the sole book-running manager for the offering. The company's strategy centers on developing sustainable, nature-derived products for treating chronic wounds, targeting the growing market driven by aging populations and increasing prevalence of diabetes, obesity, and cardiovascular ailments.
Cuprina Holdings (CUPR), a biomedical and biotechnology company focused on chronic wound management and cosmeceuticals, has announced the pricing of its Initial Public Offering (IPO). The company is offering 3,000,000 Class A Ordinary Shares at $4.00 per share, with an additional 45-day option for underwriters to purchase up to 450,000 shares.
The IPO is expected to generate gross proceeds of $13.80 million (assuming full exercise of the over-allotment option), before deducting underwriting costs and offering expenses. Trading will commence on NASDAQ under the symbol 'CUPR' on April 10, 2025, with the offering scheduled to close on April 11, 2025. R. F. Lafferty & Co. is serving as the sole book-running manager for the offering.